BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bio3 Research And Creabilis Therapeutics Sign Research Agreements With Cephalon, Inc. (CEPH)


12/8/2005 10:32:04 AM

COLLERETTO GIACOSA (TURIN) and MILAN, Italy, Dec. 7 /PRNewswire/ -- Bio3 Research s.r.l., and Creabilis Therapeutics S.p.A. today announced agreements with Cephalon, Inc. to evaluate the research compound K252a for its potential to topically treat psoriasis and for potential use in the prevention and treatment of restenosis. Creabilis Therapeutics owns patent applications covering K252a-based products for the treatment of psoriasis.

Bio3 Research and Creabilis Therapeutics co-own a patent application covering the use of K252a, a compound to prevent and treat restenosis and other cardiovascular disorders. Cephalon has proprietary rights in certain production processes for the compound. Also, with respect to the prevention and treatment of restenosis, Bio3 Research retains the right to collaborate with third parties in combining K252a with drug eluting stents. Other terms of the agreements were not disclosed.

Under the agreement, Cephalon has an exclusive option to develop and commercialize K252a-based products that may result from research performed by Creabilis Therapeutics and Bio3 Research.

"This agreement with Cephalon is a great opportunity for Creabilis Therapeutics because it enables us to accelerate the development process of this promising compound," said Dr. Silvano Fumero, the company's CEO. "We expect to file the INDs by the end of 2006."

Francesco Paolo Pilato, President and CEO of Bio3 Research, said, "We are delighted to have entered into this agreement with Cephalon, and we believe it is a great opportunity for our company to accelerate the ongoing development process at Creabilis Therapeutics. This research is part of Bio3's strong IP position in the field of HMGB1-related cardiovascular disorders."

About Creabilis Therapeutics S.p.A.

Creabilis Therapeutics S.p.A. is a privately owned drug-discovery and development company, founded in 2003 and located in the Bioindustry Park of Canavese, near Turin. The company's activity focuses mainly on DNA-binding proteins, such as HMGB1, as pharmacological targets for novel classes of inhibitors/antagonists to be developed as therapeutics. This portfolio is complemented by selected projects in related biochemical or clinical areas. Additional information on Creabilis Therapeutics can be obtained from http://www.creabilistherapeutics.com or by e-mail: info@creabilistherapeutics.com .

About Bio3 Research s.r.l.

Bio3 Research s.r.l., an Italian company founded in 2001, has headquarters in Milan and an office at the Bioindustry Park of Canavese (Turin). Bio3 Research works with research institutions, individual scientists and early- stage companies to identify, protect and exploit commercially promising intellectual property in the life sciences. Such assistance may include pre- clinical development and negotiation of strategic industrial partnerships. Bio3 Research's activity focuses mainly on the field of HMGB1-related cardiovascular disorders and use of HMGB1 and its fragments in connective tissue regeneration. Other fields of interest include skin and renal diseases. Additional information on Bio3 Research can be obtained from http://www.bio3research.com or by e-mail: info@bio3research.com .

This release was issued through The Xpress Press News Service, merging e- mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com .

Contact: Anna Oderda, 0039.0125.53543

Creabilis Therapeutics S.p.A.

CONTACT: Anna Oderda, Creabilis Therapeutics S.p.A., +011-0039-0125-53543,or aoderda@creabilistherapeutics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES